Poliovirus vaccination options for achieving eradication and securing the endgame

Current Opinion in Virology

Volumn 3, Issue 3, 2013, Pages 309-315

  Estívariz, Concepción F ^a   Pallansch, Mark A ^a   Anand, Abhijeet ^a   Wassilak, Steven G ^a   Sutter, Roland W ^b   Wenger, Jay D ^c   Orenstein, Walter A ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INACTIVATED VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; TRIPLE VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIPHTHERIA; ERADICATION THERAPY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MEASLES; MUCOSAL IMMUNITY; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEROCONVERSION; SEROPREVALENCE; SEROTYPE; TETANUS; TREATMENT RESPONSE; VACCINATION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS;

EID: 84880275738     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.05.007     Document Type: Review

References (50)

1. W.R. Dowdle, and S.L. Cochi Global eradication of poliovirus: history and rationale B.L. Semler, E. Wimmer, Molecular Biology of Picornaviruses 2002 ASM Press 473 480
2. The Global Polio Eradication Initiative Data and Monitoring 2013 Available at: http://www.polioeradication.org (accessed 22.01.13)
3. R.W. Sutter, and P.A. Patriarca Inactivated and live, attenuated poliovirus vaccines: mucosal immunity E. Kurstak, Measles and Poliomyelitis 1993 Springer-Verlag 279 293
4. R.W. Sutter, O.M. Kew, S.L. Cochi, and R.B. Aylward Poliovirus vaccine - live S.A. Plotkin, W.A. Orenstein, P.A. Offit, Vaccines edn 6 2013 Elsevier 598 645
5. E. Vidor, and S.A. Plotkin Poliovirus vaccine - inactivated S.A. Plotkin, W.A. Orenstein, P.A. Offit, Vaccine edn 6 2013 Elsevier 573 597
6. M. Roivainen, C.J. Thoden, M. Stenvik, T. Poyry, and T. Hovi Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children J Med Virol 23 1987 249 256
7. N.C. Grassly, H. Jafari, S. Bahl, R. Sethi, J.M. Deshpande, C. Wolff, R.W. Sutter, and R.B. Aylward Waning intestinal immunity after vaccination with oral poliovirus vaccines in India J Infect Dis 205 2012 1554 1561
8. World Health Organization Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Wkly Epidemiol Rec 23 2010 213 228
9. N. Nathanson, and O.M. Kew From emergence to eradication: the epidemiology of poliomyelitis deconstructed Am J Epidemiol 172 2010 1213 1229
10. V.M. Caceres, and R.W. Sutter Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication Clin Infect Dis 33 2001 531 541
11. N. el-Sayed, Y. el-Gamal, A.A. Abbassy, I. Seoud, M. Salama, A. Kandeel, E. Hossny, A. Shawky, H.A. Hussein, and M.A. Pallansch Monovalent type 1 oral poliovirus vaccine in newborns N Engl J Med 359 2008 1655 1665
12. Centers for Disease Control and Prevention Progress toward poliomyelitis eradication - India, January 2007-May 2009 MMWR Morb Mortal Wkly Rep 58 2009 719 723
13. Centers for Disease Control and Prevention Progress toward interruption of wild poliovirus transmission - worldwide, 2009 MMWR Morb Mortal Wkly Rep 59 2010 545 550
14. S.L. Cochi, and R.W. Linkins The final phase of polio eradication: new vaccines and complex choices J Infect Dis 205 2012 169 171
15. R.W. Sutter, T.J. John, H. Jain, S. Agarkhedkar, P.V. Ramanan, H. Verma, J. Deshpande, A.P. Singh, M. Sreevatsava, and P. Malankar Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial Lancet 376 2010 1682 1688
16. Centers for Disease Control and Prevention Update on vaccine-derived polioviruses - worldwide, April 2011-June 2012 MMWR Morb Mortal Wkly Rep 61 2012 741 746
17. Centers for Disease Control and Prevention Outbreaks following wild poliovirus importations - Europe, Africa, and Asia, January 2009-September 2010 MMWR Morb Mortal Wkly Rep 59 2010 1393 1399
18. M.K. Patel, M.K. Konde, B.H. Didi-Ngossaki, E. Ndinga, R. Yogolelo, M. Salla, K. Shaba, J. Everts, G.L. Armstrong, and D. Daniels An outbreak of wild poliovirus in the Republic of Congo, 2010-2011 Clin Infect Dis 55 2012 1291 1298
19. Centers for Disease Control and Prevention Outbreak of polio in adults - Namibia, 2006 MMWR Morb Mortal Wkly Rep 55 2006 1198 1201
20. Centers for Disease Control and Prevention Poliomyelitis outbreak - Republic of the Congo, September 2010-February 2011 MMWR Morb Mortal Wkly Rep 60 2011 312 313
21. Centers for Disease Control and Prevention Progress toward interruption of wild poliovirus transmission - worldwide, January 2011-March 2012 MMWR Morb Mortal Wkly Rep 61 2012 353 357
22. World Health Organization Meeting of the Strategic Advisory Group of Experts on immunization. November 2012 - conclusions and recommendations Wkly Epidemiol Rec 88 2013 1 16
23. Global Polio Eradication Initiative Polio Eradication Endgame (2013-2018) Strategic Plan and Legacy Planning (draft) 2013 Available at http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/ GPEIStrategicPlan-DRAFT07Dec2012.pdf (accessed 05.01.13)
24. S. Wassilak, M.A. Pate, K. Wannemuehler, J. Jenks, C. Burns, P. Chenoweth, E.A. Abanida, F. Adu, M. Baba, and A. Gasasira Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population J Infect Dis 203 2011 898 909
25. M. Laassri, K. Lottenbach, R. Belshe, M. Wolff, M. Rennels, S.A. Plotkin, and K. Chumakov Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains J Infect Dis 192 2005 2092 2098
26. I.M. Onorato, J.F. Modlin, A.M. McBean, M.L. Thoms, G.A. Losonsky, and R.H. Bernier Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines J Infect Dis 163 1991 1 6
27. The Cuba IPV Study Collaborative Group Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba N Engl J Med 356 2007 1536 1544
28. B.J. Moriniere, F.P. van Loon, P.H. Rhodes, M.L. Klein-Zabban, B. Frank-Senat, J.E. Herrington, M.A. Pallansch, and P.A. Patriarca Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine Lancet 341 1993 1545 1550
29. C.F. Estivariz, H. Jafari, R.W. Sutter, T.J. John, V. Jain, A. Agarwal, H. Verma, M.A. Pallansch, A.P. Singh, and S. Guirguis Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad Lancet Infect Dis 12 2012 128 135
30. Oliver Wyman Inc. The supply landscape and economics of IPV-containing combination vaccines: key findings Report Commissioned by the Bill & Melinda Gates Foundation, Prepared by Oliver Wyman 2012 Available at: http://www.polioeradication.org/Portals/0/Document/Resources/ SupplyLandscapeEconomics.09.06.2010.pdf (accessed 12.06.12)
31. J. Hickling, R. Jones, and N. Nundy Improving the Affordability of Intactivated Poliovirus Vaccine (IPV) for use in Low- and Middle-Income Countries 2012 Available at: http://www.path.org (accessed 12.06.12)
32. T. Tulchinsky, Y. Abed, S. Shaheen, N. Toubassi, Y. Sever, M. Schoenbaum, and R. Handsher A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas Am J Public Health 79 1989 1648 1652
33. Macro International Inc. Demographic Health Surveys 2012 Macro International Inc.
34. B.G. Weniger New high speed jet injectors for mass vaccinationL pros and cons of DCJIs versus MUNJIs Proceedings of the Global Vaccine Research Forum Montreux, Switzerland 2004 Biologicals IVa: WHO
35. R.J. Tebbens, M.A. Pallansch, O.M. Kew, V.M. Caceres, H. Jafari, S.L. Cochi, R.W. Sutter, R.B. Aylward, and K.M. Thompson Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication Risk Anal 26 2006 1471 1505
36. World Health Organization Meeting of the Strategic Advisory Group of Experts on immunization. April 2012 - conclusions and recommendations Wkly Epidemiol Rec 21 2012 201 216
37. N. Ion-Nedelcu, P.M. Strebel, F. Toma, S. Biberi-Moroeanu, M. Combiescu, A. Persu, A. Aubert-Combiescu, S.A. Plotkin, and R.W. Sutter Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994 J Infect Dis 175 Suppl. 1 1997 S241 S246
38. L.N. Alexander, J.F. Seward, T.A. Santibanez, M.A. Pallansch, O.M. Kew, D.R. Prevots, P.M. Strebel, J. Cono, M. Wharton, and W.A. Orenstein Vaccine policy changes and epidemiology of poliomyelitis in the United States JAMA 292 2004 1696 1701
39. S. Resik, A. Tejeda, R.W. Sutter, M. Diaz, L. Sarmiento, N. Alemani, B. Galindo, A. Burton, M. Friede, and M. Landaverde Priming following Inactivated Poliovirus Vaccine: an affordable strategy for inducing a population immunity base N Engl J Med 368 2013 416
40. S. Resik, A. Tejeda, P.M. Lago, M. Diaz, A. Carmenates, L. Sarmiento, N. Alemani, B. Galindo, A. Burton, and M. Friede Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba J Infect Dis 201 2010 1344 1352
41. F.R. Vogel, and S.L. Hem Immunologic adjuvants S.A. Plotkin, Vaccines edn 5 2008 Saunders Orenstein, WA 59 71
42. S.L. Baldwin, C.B. Fox, M.A. Pallansch, R.N. Coler, S.G. Reed, and M. Friede Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions Vaccine 29 2011 644 649
43. G. Liao, R. Li, C. Li, M. Sun, Y. Li, J. Chu, S. Jiang, and Q. Li Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial J Infect Dis 205 2012 237 243
44. P. Verdijk, N.Y. Rots, and W.A. Bakker Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains Expert Rev Vaccines 10 2011 635 644
45. A.M. McBean, M.L. Thoms, P. Albrecht, J.C. Cuthie, and R. Bernier Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines Am J Epidemiol 128 1988 615 628
46. S. Simasathien, S. Migasena, C. Beuvery, G. van Steenis, R. Samakoses, P. Pitisuttitham, and T. Vesikari Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants Scand J Infect Dis 26 1994 731 738
47. A.J. Mohammed, S. AlAwaidy, S. Bawikar, P.J. Kurup, E. Elamir, M.M. Shaban, S.M. Sharif, H.G. van der Avoort, M.A. Pallansch, and P. Malankar Fractional doses of inactivated poliovirus vaccine in Oman N Engl J Med 362 2010 2351 2359
48. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand J Infect Dis 175 1997 S215 S227
49. G.H. Dayan, M. Thorley, Y. Yamamura, N. Rodriguez, S. McLaughlin, L.M. Torres, A. Seda, M. Carbia, L.N. Alexander, and V. Caceres Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico J Infect Dis 195 2007 12 20
50. J. Cadorna-Carlos, E. Vidor, and M.-C. Bonnet Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines Int J Infect Dis 16 2012 e110 e116